scholarly journals Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in determination of prostate cancer and importance of prostate volume

2014 ◽  
Vol 8 (1-2) ◽  
pp. 81 ◽  
Author(s):  
Cavit Ceylan ◽  
Omer Gokhan Doluoglu ◽  
Erdogan Aglamis ◽  
Ozkan Baytok

Introduction: In this study, we evaluate the relationship between increasing core numbers and cancer detection rate.Methods: We included 1120 patients with prostate-specific antigen levels ≤20 ng/mL and/or suspicious digital rectal examination findings in this study. All patients had a first-time prostate biopsy and 8, 10, 12, 16, and 20 core biopsies were taken and examined in different groups during the study. Multiple logistic regression analysis was made to reach the factor affecting the cancer detection rate between the patients with and without cancer. A p < 0.05 was considered statistically significant.Results: Out of 1120 patients, 221 (19.7%) had prostate cancer. Again of the total 1120 patients, 8 core biopsies were taken from 229 (20.4%); 10 core biopsies from 473 (42.2%); 12 core biopsies from 100 (8.9%); 16 core biopsies from 140 (12.5%); and 20 core biopsies from 178 (15.9%) patients. The increase in the core number increased the cancer detection rate by 1.06 times (p = 0.008).Conclusions: As long as prostate volume increases, increasing the core number elevates the cancer detection rate. Thus, the rate of missed cancer will be reduced and the rates of unnecessary repetitive biopsy decreases.

2017 ◽  
Vol 89 (3) ◽  
pp. 245 ◽  
Author(s):  
Andrea Fabiani ◽  
Emanuele Principi ◽  
Alessandra Filosa ◽  
Lucilla Servi

Dear Editors,We read with interest the article by Di Franco and co-workers (1). The introduction of prostatic magnetic resonance and the relative fusion-biopsy have not yet allowed the expected improvements in prostate biopsy. To our knowledge, there are no works that demonstrate the superiority of fusion techniques on the remaining ultrasound guided prostate biopsies that are still the widely used in the diagnosis of prostate cancer. Furthemore, these technologies are expensive exams and they are not yet available in all centers, especially in those minors. We work at a “minor” center and we always keep in mind that the goal of  prostatic biopsy is the diagnosis and the staging of prostatic neoplasms.. However, it remains uncertain which of the two techniques, transperineal (TP) or transrectal (TR), is superior in terms of detection rate during first biopsy setting. Several studies have compared the prostate cancer detection rate but TR and TP access route in prostatic gland sampling seems to be equivalent in terms of efficiency and complications, as reported by Shen PF et al. (2), despite several methodological limitations recognized in their work. The results reported by Di Franco CA et al. represent the real life experience of most urologists that perform the PB based on their own training experience and available technical devices. From an historical viewpoint, the TP route has been the first one to be used to reach the prostate, both for diagnostic and therapeutic purposes. To date, because it seems to be more invasive and difficult, the TP route is less used worldwide than the TR one (2). Theoretically, the TP approach should detect more prostate cancer than the TR way  because the cores of the TP approach are directed longitudinally to the peripheral zone and the anterior part of the prostate (4). The results reported by Di Franco et al. seems to confirm these considerations. However, our real life experience differ from the conclusions reached in their work. We recently conducted a prospective evaluation of 352 patients who underwent their first prostate biopsy because of a suspicious of prostate cancer (elevated prostate specific antigen (PSA) and/or abnormal digital rectal examination and/or abnormal findings on transrectal prostatic ultrasound). Patients was randomized as following. A total of 187 patients (Group A) underwent a prostatic biopsy with a transperineal approach in a lithotomic position,  using a biplane probe (8818 BK Medical, Denmark) and a fan technique with a single perineal median access (5). The remnants 165 patients (Group B) underwent a transrectal ultrasound guided prostate biopsy in a left lateral position, using a end fire probe configuration (8818 BK Medical, Denmark) and a sagittal technique. The bioptic prostatic mapping was performed with a 12-core scheme sec. Gore (3) by a single experienced operator and the histopathologic evaluation was performed by a single dedicated uro-pathologist. Statistical evaluations were made with a T Student test  (p<0,005). Group A and Group B was similar in term of mean patient age (67,9 years and 67 years respectively), mean total PSA (12,1 ng/ml vs 12 ng/ml) and digital rectal examination positivity (22% vs 29%).  The global cancer detection rate was 33,69% (63/187) in the transperineal prostate biopsy group and 48,48 % (80/165) in the transrectal approach (p=0.0047).  No significant statistical differences were found in the complications rates between the two groups. Statistical evaluation of site of tumor localization reveal only a trend to statistical significance in apical site tumors diagnosed with the TR approach versus the TP technique. The TR approach had a better diagnostic accuracy than TP technique in case of PSA<4 ng/ml, intermediate prostate volume (30 and 50 ml), normal digital rectal examination without any relationship with the patient age. In our experience, two aspect may explain the difference between the two group in term of global detection rate. First, we usually perform transrectal biopsy with a sagittal technique that simulates the transperineal way of needle incidence with the prostatic gland. The lateral and anterior gland portions may be sampled more accurately. Second, our transperineal approach consists in a single perineal median access that can make more difficult the gland sampling between the two lobes. However, there was no significant difference in core positivity rate at the peripheral zone, medium gland, apex or any other site such as reported in many randomized clinical trials (2). Unlike the conclusions reported by Di Franco et al., in our experience we found a statistically significant difference between the TR and TP approach, at the first biopsy setting, in term of global cancer detection rate. No differences were found in terms of complications. Moreover, our data suggest that TR approach had a better diagnostic accuracy than TP technique in case of  PSA<4 ng/ml, prostate volume 30-50 ml, normal digital rectal examination without any relationship with the patient age. The further step of the statistical evaluation of our data will be the definition of the possibility that the TR biopsy determine a better staging of prostate cancer than TP approach as first procedure.    REFERENCES 1)      Di Franco CA, Jallous H., Porru D. et al. A retrospective comparison between transrectal and transperineal prostate biopsy in the detection of prostate cancer Arch Ital Urol Androl 2017; 89(1), 55-92)      Shen FP, Zhu YC, Wei WR et al. The results of transperineal vs transrectal prostate biopsy: a systematic review and meta-analysis. Asian Journal of Androl 2012; 14: 310-15.3)      Gore JL., Shariat SF, Miles BJ., et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001; 165: 1554-59.  4)      Abdollah F., Novara G., Briganti A. et al. Trasrectal versus transperineal saturation re biopsy of the prostate: is there a difference in cancer detection rate? Urology 2011; 77:9215)      Novella G, Ficarra V, Galfano A, et al. Pain assessment after original transperineal prostate biopsy using a coaxial needle. Urology. 2003; 62 : 689-92. 


2021 ◽  
Author(s):  
Victor Mihail Cauni ◽  
Dan Stanescu ◽  
Florin Tanase ◽  
Bogdan Mihai ◽  
Cristian Persu

Aim: Magnetic resonance/ ultrasound fusion targeted biopsy (Tbs) is widely used for diagnosing prostate cancer (PCa). The aim of our study was to compare the cancer detection rate (CDR) and the clinically significant prostate cancer detection rate (csPCa) of the magnetic resonance/ultrasound fusion targeted biopsy with those of the standard systematic biopsy (Sbs) and of the combination of both techniques.Material and methods: A total of 182 patients underwent magnetic resonance/ultrasound fusion Tbs on the prostate for PCa suspicion based on multiparametric magnetic resonance imaging (mMRI) detection of lesions with PI-RADSv2 score ≥3. A total of 78 patients had prior negative biopsies. Tb was performed by taking 2-4 cores from each suspected lesion, followed by Sb with 12 cores. We evaluated the overall detection rate of PCa and clinically significant prostate cancer, defined as any PCa with Gleason score ≥3+4.Results: Median prostate specific antigen (PSA) level pre-biopsy was 7.4 ng/ml and median free-PSA/PSA ratio was 10.2%. Patient median age was 62 years old. PIRADSv2 score was 3 in 54 cases, 4 in 96 cases and 5 in 32 cases. PI-RADS-dependent detection rate of Tbs for scores 3, 4 and 5 was 25.9%, 65.6% and 84.4%, respectively, with csPCa detection rates of 24.1%, 54.2%, and 71.9%. Overall detection rate was 57.1% for Tbs, which increased to 60.4% by adding Sbs results. Detection rate for clinically significant prostate cancer (csPCa) was 48.4% and increased to 51.1% by adding Sbs. Overall detection rate for repeated biopsy was 50% and 68.3% for biopsy in naïve patients. Sbs detection rate was 55.5%, 8 patients having a negative biopsy on Tbs.Conclusions: When Tbs is considered due to a PI-RADS ≥3 lesion on mMRI, combined Tbs + Sbs increases the overall CDR and csPCa detection rates.


2013 ◽  
Vol 4 (2) ◽  
pp. 100 ◽  
Author(s):  
Mohamed Amine Jradi ◽  
Mohamed Dridi ◽  
Mourad Teyeb ◽  
Mokhtar Ould Sidi Mohamed ◽  
Ramzi Khiary ◽  
...  

Introduction: To increase the detection rate of prostate cancer inrecent years, we examined the increase in the number of corestaken at initial prostate biopsy. We hypothesized that an increasingnumber of cores may undermine the accuracy of models predictingthe presence of prostate cancer at initial biopsy in patientssubmitted to 20-core initial biopsy.Methods: A total of 232 consecutive patients with prostatespecificantigen (PSA) between 4 and 20 ng/mL and/or abnormaldigital rectal examination (DRE) underwent 12-core prostate biopsyprotocol (group 1) or 20-core prostate biopsy protocol (group 2).The patients were divided into subgroups according to the resultsof their serum PSA and prostate volume. We evaluated the cancerdetection rate overall and in each subgroup. Clinical datawere analyzed using chi-square analysis and the unpaired t-testor 1-way ANOVA with significance considered at 0.05.Results: The 2 groups of patients were not significantly different withregard to parameters (age, abnormal DRE and serum PSA), althoughmedian prostate volume in group 1 (57.76 ± 26.94 cc) were slightergreater than in group 2. Cancer detection rate for patients submittedto 20 prostate biopsy was higher than patients submitted to 12prostate biopsy (35.2% vs. 25%, p = 0.095). Breakdown to PSAlevel showed a benefit to 20 prostate biopsy for PSA <6 ng/mL (37.1%vs. 12.9%, p = 0.005). Stratifying results by prostate volume, wefound that the improvement of cancer detection rate with 20 prostatebiopsy was significant in patients with a prostate volume greaterthan 60 cc (55% in 20 prostate biopsy vs. 11.3% p < 0.05). Morbidityrates were identical in groups 1 and 2 with no statistically significantdifference. There appeared to be no greater risk of infectionand bleeding with 20 prostate biopsy protocol.Conclusion: The 20-core biopsy protocol was more efficient thanthe 12-core biopsy protocol, especially in patients with prostatespecific antigen <6 ng/mL and prostate volume greater than 60 cc.Introduction : Pour augmenter le taux de détection du cancer de laprostate dans un avenir rapproché, nous avons examiné l’incidenced’une hausse du nombre de carottes prélevées lors de la biopsieprostatique initiale. Notre hypothèse était qu’en raison du nombreaccru de prélèvements, la biopsie à 20 carottes pouvait réduirel’exactitude des modèles de dépistage du cancer de la prostate à labiopsie initiale.Méthodologie : Au total, 232 patients consécutifs avec des tauxd’antigène prostatique spécifique (APS) situés entre 4 et 20 ng/mLet/ou des anomalies au toucher rectal ont subi une biopsie prostatiqueà 12 (groupe 1) ou à 20 carottes (groupe 2). Les patients ontété répartis en sous-groupes en fonction de leurs taux sériques d’APSet de leur volume prostatique. Nous avons évalué le taux de dépistagedu cancer de façon globale et par sous-groupes. Les données cli -niques ont été analysées par la méthode du chi carré et du test tpour échantillons non appariés ou par analyse unilatérale de lavariance (ANOVA), avec un seuil de signification de 0,05.Résultats : On n’a noté aucune différence significative entre lesdeux groupes quant aux paramètres (âge, anomalie au toucher rectalet taux sériques d’APS), malgré que le volume prostatique médianait été légèrement supérieur dans le groupe 1 (57,76 ± 26,94 mL)par rapport au groupe 2. Le taux de dépistage du cancer avec labiopsie prostatique à 20 carottes était plus élevé que le taux obtenuavec la biopsie à 12 carottes (35,2 % vs 25 %, p = 0,095). La répartitiondes patients en fonction des taux d’APS a fait ressortir unavantage pour la biopsie à 20 carottes lorsque les taux d’APS étaientinférieurs à 6 ng/mL (37,1 % vs 12,9 %, p = 0,005). La stratificationdes données selon le volume de la prostate a montré que lahausse des taux de dépistage du cancer associée à la biopsie prostatiqueà 20 carottes était significative lorsque le volume prostatiquedépassait 60 mL (55 % pour la biopsie à 20 carottes vs 11,3 %,p < 0,05). Les taux de morbidité étaient semblables dans les deuxgroupes, la différence n’étant pas significative sur le plan statistique.La biopsie prostatique à 20 carottes ne semblait pas associéeà un risque plus élevé d’infection et d’hémorragie.Conclusion : La biopsie à 20 carottes était plus efficace que la biopsieà 12 carottes, surtout chez les patients dont le taux d’APS était


2021 ◽  
Author(s):  
Javangula Venkata Surya Prakash ◽  
Thiruvarul PV ◽  
Vetrichandar Sattanathan ◽  
Krishnan Vembu Arasi ◽  
ArunKumar Paranjothi ◽  
...  

Abstract INTRODUCTION: Prostate cancer is the second most common cancer diagnosed in men with an estimated 1.2 million diagnoses worldwide. The incidence of Prostate cancer is higher in western countries and low in Asian countries. The need for prostate biopsy is based on PSA levels. The general cut off PSA value for the Indian population is 4.0 ng/mL. The reported cancer detection rate of TRUS-guided biopsies is around 30 percent in western countries and lesser in Asian countries, including India, particularly for serum PSA values less than 20 ng/mL indicating that many of the Indian patients are subjected to unnecessary biopsy which adds up to distress to these patients.PURPOSE: To determine the cancer detection rate of TRUS-guided prostate biopsy in the Indian population at different serum Prostate-Specific Antigen levels and determine a PSA cut-off level to avoid unnecessary biopsies.MATERIALS AND METHODS:All symptomatic patients who underwent TRUS guided biopsy for raised serum PSA levels between 4 - 20 ng/mL were included. The patients were categorized into four groups corresponding to the PSA levels ranging between 4-6 ng/mL, 6- 8 ng/mL, 8-10 ng/mL, and 10-20 ng/mL respectively, and cancer detection rate in each group were statistically analyzed.RESULTS:The sensitivity, specificity, and positive predictive value of TRUS guided biopsy are 75%, 95%, and 98% respectively in our study. The overall cancer detection rate of TRUS biopsy in our series was 18.4%. The PSA cut-off to do biopsy was derived by ROC curve as 8.9 ng/ml for all the men. CONCLUSION: The PSA cut-off of 4.0 ng/mL is currently used as an indication for biopsy among men of all ages in the Indian population. We recommend a raise in cut-off to 8.9 ng/mL to avoid unnecessary TRUS-guided biopsies in the Indian population.


Sign in / Sign up

Export Citation Format

Share Document